礼来Retevmo作为辅助疗法显著改善早期RET融合阳性肺癌患者的无事件生存期

投资观察
Feb 16

2月16日——礼来公司宣布,其药物Retevmo(selpercatinib)作为辅助疗法,在治疗早期RET融合阳性肺癌的临床试验中展现出显著的无事件生存期获益。根据LIBRETTO-432三期研究结果,该试验达到了主要终点,显示患者的无事件生存期获得明显改善。

与此同时,总生存期数据初步呈现有利于selpercatinib的趋势,但由于观察事件数量较少,分析时数据尚不成熟,需要进一步随访验证。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10